title: A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.
abstract: The high-affinity reductive iron uptake system that includes a ferroxidase (Cfo1) and an iron permease (Cft1) is critical for the pathogenesis of Cryptococcus neoformans. In addition, a mutant lacking CFO1 or CFT1 not only has reduced iron uptake but also displays a markedly increased susceptibility to azole antifungal drugs. Altered antifungal susceptibility of the mutants was of particular interest because the iron uptake system has been proposed as an alternative target for antifungal treatment. In this study, we used transcriptome analysis to begin exploring the molecular mechanisms of altered antifungal susceptibility in a cfo1 mutant. The wild-type strain and the cfo1 mutant were cultured with or without the azole antifungal drug fluconazole and their transcriptomes were compared following sequencing with Illumina Genome Analyzer IIx (GAIIx) technology. As expected, treatment of both strains with fluconazole caused elevated expression of genes in the ergosterol biosynthetic pathway that includes the target enzyme Erg11. Additionally, genes differentially expressed in the cfo1 mutant were involved in iron uptake and homeostasis, mitochondrial functions and respiration. The cfo1 mutant also displayed phenotypes consistent with these changes including a reduced ratio of NAD(+)/NADH and down-regulation of Fe-S cluster synthesis. Moreover, combination treatment of the wild-type strain with fluconazole and the respiration inhibitor diphenyleneiodonium dramatically increased susceptibility to fluconazole. This result supports the hypothesis that down-regulation of genes required for respiration contributed to the altered fluconazole susceptibility of the cfo1 mutant. Overall, our data suggest that iron uptake and homeostasis play a key role in antifungal susceptibility and could be used as novel targets for combination treatment of cryptococcosis. Indeed, we found that iron chelation in combination with fluconazole treatment synergistically inhibited the growth of C. neoformans.
authors.affiliation: Department of Biotechnology, Chung-Ang University, Anseong 456-756, Republic of Korea.
authors.forename: Jeongmi
authors.initials: J
authors.lastname: Kim
authors.forename: Yong-Joon
authors.initials: YJ
authors.lastname: Cho
authors.forename: Eunsoo
authors.initials: E
authors.lastname: Do
authors.forename: Jaehyuk
authors.initials: J
authors.lastname: Choi
authors.forename: Guanggan
authors.initials: G
authors.lastname: Hu
authors.forename: Brigitte
authors.initials: B
authors.lastname: Cadieux
authors.forename: Jongsik
authors.initials: J
authors.lastname: Chun
authors.forename: Younghoon
authors.initials: Y
authors.lastname: Lee
authors.forename: James W
authors.initials: JW
authors.lastname: Kronstad
authors.forename: Won Hee
authors.initials: WH
authors.lastname: Jung
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D001393:Azoles / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D002570:Ceruloplasmin / Q000235:genetics / Q000378:metabolism; D003453:Cryptococcosis / Q000382:microbiology; D003455:Cryptococcus neoformans / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000378:metabolism*; D025141:Drug Resistance, Fungal; D004875:Ergosterol / Q000096:biosynthesis; D015725:Fluconazole / Q000494:pharmacology; D005656:Fungal Proteins / Q000235:genetics / Q000378:metabolism; D017353:Gene Deletion; D015966:Gene Expression Regulation, Fungal / Q000187:drug effects; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008826:Microbial Sensitivity Tests
chemical_list: D000935:Antifungal Agents; D001393:Azoles; D005656:Fungal Proteins; D015725:Fluconazole; D007501:Iron; D002570:Ceruloplasmin; D004875:Ergosterol